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Equity Valuation – OdontoPrev “ODPV3”         19th  of October 2015  
Conservative Scenario: Macroeconomic Slowdown 
OdontoPrev’s valuation exercise contemplates the current negative 
macroeconomic scenario of Brazil. As a result, the future growth 
assumptions are fairly conservative (i.e. sales are projected to deliver 
growth slightly above inflation levels). The company has improved its 
operational efficiency, showing a lower dental loss ratio in the last 
periods and has also implemented new and more reliable distribution 
channels with lower commission costs, therefore overcoming the 
challenges presented by the unfavorable circumstances of the Brazilian 
economy. 
Smile, There is Further Possibility for Growth 
After delivering growth based on the expansion of corporate members, 
the company has now changed its focus to SME’s and individual 
contracts, which represent today less than 20% of the total portfolio. 
These segments are considered crucial for the company revenues’ 
expansion, allowing higher margins than the corporate segment. For 
that, the associations with Bradesco and Banco do Brasil and the new 
distribution channels of the company arise as a key factor to succeed 
in this operation. None of OdontoPrev’s competitors have anything 
close to what Bradesco and Banco do Brasil have to offer, so the market 
leader should remain with the brightest smile. 
OdontoPrev’s Financial Indicators Forecast  
 
 
ODPV3                               HOLD 
Last Price (28/08/2015)             R$ 9.8 
Target-Price (31/12/2015)      R$ 10.5 
Upside Potential                          6.7%  
Equity Value (R$ million)          5,201 
1 Month Change                       (7.2%) 
52w Low                                     R$ 8.6 




















Valuation               R$ Million 
Enterprise Value 2015E              5,234 
Net Debt 2015E                           (316) 
Equity Value 2015E                    5,550 
Shares (million)                             531 
Cost of Equity (Re)                    11.3% 














Multiples                        2015 
PER                                                       24x 









OdontoPrev Key Indicators 2014 2015 2016 2017 2018 2019 2020 2021
Average Members (thousand) 6,244  6,488  6,754  7,121  7,508  7,917  8,347  8,801  
Average Ticket (R$/Live/Month) 15.43 16.64 17.44 18.20 18.95 19.73 20.52 21.35
NOR (R$ million) 1,156  1,258  1,414  1,555  1,707  1,874  2,056  2,255  
NOR Growth 9% 12% 10% 10% 10% 10% 10%
EBIT (R$ million) 60 273 325 389 433 482 544 602
Net Income (R$ million) 195 235 281 315 354 406 449 495



















Title: OdontoPrev – Equity Valuation 
Author: Pedro Oliveira 
The aim of this master thesis is to calculate the most accurate price per share of OdontoPrev 
(ODPV3) on the 31st of December 2015. To perform that, a review of the related literature is 
carried out to realize that the Discounted Cash Flow valuation model, using the Cost of 
Equity as a discount rate, is the most suitable method to value the company. 
After discounting the free cash flows to equity, the result is a market capitalization of R$ 
5,550 million, correspondent to a price per share of R$ 10.45. Besides that, the relative 
valuation (multiples) approach is also used to confirm the accuracy of the price per share 
under the discounted cash flow valuation, which displays an upside potential of 6.7% when 
compared with the share traded on the 28th of August 2015 – R$ 9.79. 
This makes it believable that OdontoPrev is being slightly undervalued by the market, 
making it a good opportunity to hold the investment. A “Hold” recommendation is the result 
of the assumptions on the future growth prospects of the company, taking into consideration 
that macroeconomic events occurring in emerging markets (i.e. Brazil) may have significant 
impact on the valuation. 
  




This valuation exercise proved to be a perfect tool to strengthen my finance knowledge, in 
particular in the field of stock market and equities, while encouraging me to pursue a career 
in this area. 
Firstly, I would like to thank Professor José Carlos Tudela Martins for the constant 
availability, guidance and help. 
Secondly, I am grateful to OdontoPrev’s Investor Relations department for all the support 
along this period, with a special thanks to José Roberto Pacheco, Roberta Carneiro and 
Dárcio Nunciatelli. 
Finally, this master thesis is dedicated to all my beloved family, friends and girlfriend, who 
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iii.      Introduction 
Valuation is the practice of measuring the value of an asset, being critical in investments and 
portfolio management. To outperform in equity markets, one should buy undervalued stocks 
and sell overvalued stocks, by supporting his decision on accurate estimates of its fair value. 
Therefore, a recommendation for the investment plan, proposing a buy, hold or sell strategy 
is given. 
Accordingly, the aim of this master thesis is to calculate the value per share of OdontoPrev 
(ODPV3), on the 31st of December 2015. There is no consensus on what is the best valuation 
model to value the company chosen, as so, the relevant literature is initially discussed by 
examining different author’s approaches, presented in several articles, books and journals. 
There is also the need to realize what are the characteristics of the environment in which 
OdontoPrev operates. The company is the market leader in the dental care sector, however, 
the impact of factors such as the uncertainty surrounding insurance firms, regulatory settings 
of the sector and fierce competition has to be measured, being fundamental for the 
performance within the industry. 
Under the DCF model – using the FCFE approach (discounted at the cost of equity) – and 
the multiples approach to value OdontoPrev, the outcome is a stock price believed to reflect 
the expectations about the future performance of the company. Moreover, a sensitivity 
analysis to find plausible alternative values for the price, under different scenarios, is 
performed. 
The last step of this master thesis is a comparison between the DCF valuation done with one 
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1 Literature Review 
1.1 Valuation Importance 
Valuation is one of the most essential skills in Finance ever since it can reveal opportunities 
of investment or divestment in the entire spectrum of publicly traded companies. If one reach 
to a reasonable value for a company, then can take correct decisions regarding investment: 
According to (Buffet, 1989), “It’s far better to buy a wonderful company at a fair price than 
a fair company at a wonderful price”. Thus, the more accurate valuation one performs, more 
profitable one will be because is aware of the fair price per share. 
The valuation of an asset essentially consists in predicting the future returns that a company 
can deliver and consequently discount the estimated future cash flows for today, using the 
correct discount rate. According to (Damodaran, 2002), “some assets are easier to value than 
others, the details of valuation vary from asset to asset, and the uncertainty associated with 
value estimates is different for different assets, but the core principles remain the same”.  
Valuation is the assessment of the asset’s value based either on variables related to future 
returns or through direct comparisons with similar assets. According to (Stowe et al., 2007), 
“this process includes understanding the company to be valued, forecasting the company’s 
performance, and selecting the appropriate valuation model for a given valuation task”. 
Valuation is not an exact exercise, subject to the assumptions and biases of each analyst, who 
figures a way to calculate the value of an asset. It plays an important role in many financial 
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According to (Stowe et al., 2007), valuation techniques can be applied in several 
circumstances and its main purposes are the following: 
 Stock - picking. To realize which stocks are undervalued and overvalued, guiding the 
investor to purchase, hold, or sale the stock; 
 Understanding the market. The current share prices in the market are a result of 
investors’ expectations about the performance of variables influencing the price of 
the stock (e.g., earnings growth and expected return). Analysts can estimate these 
expectations by comparing market prices with a stock’s intrinsic value; 
 Estimating the value of corporate events. Market professionals use valuation 
techniques to analyze proposed corporate mergers & acquisitions (M&A), 
management buyouts (MBOs) and financial restructuring; 
 Corporate governance planning. Evaluate the effects of proposed corporate strategies 
on the firm’s stock price; 
 Communication. Valuation provides a discussion between company, analysts and 
investors to evaluate the company’s performance and future policies; 
 Valuation of private owned businesses. To determine the value of firms that are not 
publicly traded, investors typically rely on valuations made by investment banks, 
which were the ones with the access to information and mandated for that purpose; 
 Portfolio management. Equity valuation is the starting point for the construction of a 
portfolio of stocks, being a more powerful tool when used in a group context because 
mitigates the diversifiable risk of the market; 
As described above, there are several purposes for valuing a company, however, this thesis 
will be focused on the first one (stock - selection), aiming to reach the price per share of the 




Equity Valuation - OdontoPrev 
 
9  
1.2 Valuation Steps 
Valuation is perceived as a complex process with several stages that should be followed in a 
particular way. According to (Stowe et al., 2007), “each individual valuation that an analyst 
undertakes can be viewed as a process with the following five steps”:  
 “Understanding the business”. Industry and company overview, by examining firm 
strategies and the financial statements; 
 “Forecasting company performance”. Forecasted revenues and earnings are key to 
estimate the value of the company;  
 “Selecting the appropriate valuation model”. Each industry or company type has a 
specific valuation model that lead to a more accurate valuation, hence an overall 
analysis should be embraced; 
 “Converting forecasts to a valuation”; 
 “Making the investment decision”. After valuing the company, a recommendation 
should be given – hold, buy or sell the asset; 
In the next stage of this literature review, a detailed discussion of the third step (“selecting 
the appropriate valuation model”) will be addressed, by stressing out the main and current 
valuation models as well as the elements and formulas supporting them. All the approaches 
are relative to author’s different points of view. The model that best fits the company will be 
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1.3 Valuation Methods 
There are numerous ways to value a company but being more specific and following 
(Damodaran, 2005), “In general terms, there are four approaches to valuation. The first, 
discounted cash flow valuation, relates the value of an asset to the present value of expected 
future cash flows on that asset. The second, liquidation and accounting valuation, is built 
around valuing the existing assets of a firm, with accounting estimates of value or book value 
often used as a starting point. The third, relative valuation, estimates the value of an asset by 
looking at the pricing of 'comparable' assets relative to a common variable like earnings, cash 
flows, book value or sales. The final approach, contingent claim valuation, uses option 
pricing models to measure the value of assets that share option characteristics”. There is a 
wide range of methods for valuing an asset, nevertheless, to choose the most relevant for the 
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1.3.1 Discounted Cash Flow Approach (“DCF”) 
Discounted Cash Flow valuation, as implicit in the concept, is based on future cash flows to 
reach the firm value as of today. For that, future cash flows are discounted for today, using 
the right cost of capital. According to (Fernandez, 2007), the general formula for discounting 
cash flows is given by the following equation: 
Equation 1 – Discounted Cash Flows 












                                  
Where:             
            CFi = cash flow generated by the company in the period i  
   RVn = residual value (terminal value) of the company in the year n 
    𝑟 = appropriate discount rate  
    g =  constant growth rate after year n   
The DCF model can be computed through several ways. Following (Stowe et al., 2007), 
concerning cash flow, three main approaches are considered: 
 Dividends (Dividend Discount Model); 
 Free Cash Flow (FCFE and FCFF); 
 Residual Income; 
There is a fourth method with respect to DCF, the so called Adjusted Present Value 
(APV) which is useful to value companies where it is expected its capital structure to 
alternate. The purpose of APV valuation is to measure apart the effect of debt in the value 
of the company. In line with (Luehrman, 1997), “APV is exceptionally transparent: you 
get to see all the components of value in the analysis”. The company being analyzed 
doesn’t have and doesn´t intend to have debt, so this literature review will not deeply 
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1.3.1.1 Dividend Discount Model (“DDM”)  
Dividend Discount Model is based on expected dividends, which are the expected cash flows 
to remunerate shareholders. This approach was developed by John Burr Williams in 1938 
and assumes that the single cash flow that a shareholder has the right to receive is the dividend 
paid by the company. The general formula to compute the stock price is given by:  
Equation 2 – Value per Share according to DDM 







   𝐸(𝐷𝑃𝑆𝑡) = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑑𝑖𝑣𝑖𝑑𝑒𝑛𝑑𝑠 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 𝑡  
               𝑘𝑒 = 𝑅𝑒 = 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦   
The stock price is the value of the expected future dividends per share, discounted at the cost 
of equity. In order to forecast future dividends, accurate assumptions should be made for 
profitability and company’s dividend policy. (Stowe et al., 2007), reasons that “a discounted 
dividend approach is most suitable for dividend-paying stocks, where the company has a 
discernible dividend policy that has an understandable relationship to the company´s 
profitability and the investor has a control (minority ownership) perspective”. This model is 
only dependent of one variable (expected dividends) and could lead to a gap when the payout 
policy is under/overestimated, so this thesis will not use the DDM approach. Gordon, in 1963, 
presented the Gordon Growth Model, which is given by: 
Equation 3 – Gordon Growth Model 





  𝐸(𝐷𝑃𝑆𝑡+1) = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑑𝑖𝑣𝑖𝑑𝑒𝑛𝑑𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑛𝑒𝑥𝑡 𝑝𝑒𝑟𝑖𝑜𝑑 
              𝑘𝑒 = 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 
   𝑔 = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑔𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑒 𝑖𝑛 𝑝𝑒𝑟𝑝𝑒𝑡𝑢𝑖𝑡𝑦 
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1.3.1.2 Free Cash Flow to Equity (“FCFE”)  
The free cash flow to the equity approach values the part of the company that belongs to 
shareholders, in the same line as the Dividend Discount Model but with a key adjustment 
observed by (Damodaran, 2009): “one way to describe a free cash flow to equity model is 
that it represents a model where we discount potential dividends rather than actual 
dividends”.  
Equation 4 – Equity Value  








            𝐹𝐶𝐹𝐸𝑡 =  𝑓𝑟𝑒𝑒 𝑐𝑎𝑠ℎ 𝑓𝑙𝑜𝑤 𝑡𝑜  𝑒𝑞𝑢𝑖𝑡𝑦 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑡   
    𝑘𝑒 = 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 
To compute shareholder’s equity, the free cash flow to equity is discounted at the cost of 
equity (𝑘𝑒), representing the intrinsic risk of dividends. As stated by (Stowe et al., 2007), 
“free cash flow to equity is the cash flow available to the company’s common equity holders 
after all operating expenses, interest, and principal payments have been paid and necessary 
investments in working and fixed capital have been made”. Essentially, it is the maximum 
amount of cash that can be paid to the equity shareholders of the company after all expenses, 
reinvestment needs and debt repayment. The FCFE formula is given by: 
Equation 5 – FCFE Calculation 
𝐹𝐶𝐹𝐸 = 𝑁𝑒𝑡 𝐼𝑛𝑐𝑜𝑚𝑒 − 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠 + 𝐷𝑒𝑝𝑟𝑒𝑐𝑖𝑎𝑡𝑖𝑜𝑛𝑠
− 𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑛𝑜𝑛 𝑐𝑎𝑠ℎ 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 + 𝑁𝑒𝑤 𝐷𝑒𝑏𝑡
− 𝐷𝑒𝑏𝑡 𝑅𝑒𝑝𝑎𝑦𝑚𝑒𝑛𝑡 
This approach starts with the net income, and then subtracts capital expenditures, since they 
represent a cash outflow, same as the change in non-cash working capital. Depreciations 
should be added because they are non-cash charges. Finally, one should add new debt, net of 
debt repayments. Each of the components of the FCFE formula exposed above will be 
explained in detail in chapter 3 – valuation.  
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1.3.1.3 Free Cash Flow to Firm (“FCFF”)  
The FCFF approach values the firm as a whole – debt and equity. Accordingly, the free cash 
flows to the firm are discounted at the weighted average cost of capital (WACC), which is 
the discount rate that takes into consideration both debt and equity weighted. FCFF is 
considered the cash flow available to all type of investors:  equity holders and debt holders. 
The value of the company can be obtained as the present value of the FCFF: 
Equation 6 – Firm Value  







   𝐹𝐶𝐹𝐹𝑡 =  𝑓𝑟𝑒𝑒 𝐶𝑎𝑠ℎ 𝐹𝑙𝑜𝑤 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑖𝑟𝑚 𝑖𝑛 𝑦𝑒𝑎𝑟 𝑡   
   𝑊𝐴𝐶𝐶 = 𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 
According to (Stowe et al., 2007), “free cash flow to the firm is the cash flow available to the 
company’s suppliers of capital after all operating expenses (including taxes) have been paid 
and necessary investments in working capital (e.g., inventory) and fixed capital (e.g. 
equipment) have been made”. The FCFF formula is given by: 
Equation 7 – FCFF Calculation 
𝐹𝐶𝐹𝐹 =   𝐴𝑓𝑡𝑒𝑟 𝑡𝑎𝑥 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑖𝑛𝑐𝑜𝑚𝑒 − 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 𝐸𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒𝑠 + 𝐷𝑒𝑝𝑟𝑒𝑐𝑖𝑎𝑡𝑖𝑜𝑛𝑠
− 𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑛𝑜𝑛 𝑐𝑎𝑠ℎ 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 
According to (Damodaran, 2009) “financial service firms are best valued when using equity 
methods, rather than enterprise valuation models”. Since the company doesn’t have debt in 
its capital structure, neither intends to, therefore, the DCF valuation model used in this thesis 
was based on the FCFE approach (described above), because it discounts future cash flows 
at the cost of equity, which is the only opportunity cost that the stockholders face and the 
only financial source of company. 
 
 
Equity Valuation - OdontoPrev 
 
15  
1.3.2 Relative Valuation 
Relative valuation approach highlights the value of a company by considering a group of 
comparable companies (peer group), while looking to key common variables among them. 
Considering (Damodaran, 2005), “a potential investor in a stock tries to estimate its value by 
looking at the market pricing of “similar” stocks”. Agreeing with (Frykman & Tolleryd, 
2003), in order to compute a relative valuation multiple one should follow this steps: 
 Identification of a key variable to value the company; 
 Choose comparable companies; 
 Adjust for differences between companies; 
 Calculate multiples of the peer group; 
 Apply multiples to the chosen company to estimate enterprise value/equity; 
The valuation with multiples is computed with ratios that express the firm value in relation 
to particular variables such as net operating revenue, earnings or book value. By multiplying 
the average ratio of the peer group with the variable chosen, one obtains the firm value. 
Multiples offers several advantages to the valuation analysis for the reason that they are easy 
to calculate and give another valuation perspective – external one (peers). Consequently, one 
must identify which multiple is more appropriate to value each company, according to 
industry sector and company structure, and also take precaution on how to compute it 
correctly.  There is one important aspect relatively to which type of multiples should be used 
to value each company, it is empirically verified by (Liu, 2001) that, “the dispersion of 
pricing errors increases substantially for multiples based on historical drivers, such as 
earnings and cash flows, and is especially large for sales multiples”.  
Choosing the appropriate group of comparable companies – peer group – is one of the most 
challenging tasks in relative valuation, distinguishing high-level analysts from common ones. 
The fact that a company is in the same industry is not sufficient condition for belonging to 
the peer group since it’s reasonable for companies in the same industry to have completely 
different growth patterns, capital structure and risk. This fact is easily explained by the 
discrepancy of stock’s performance within an industry. According to (Damodaran, 2002), the 
peer group members should be similar to the company being valued, namely in cash flows, 
growth potential and risk Accordingly, (Goedhart, 2005) recommends to be considered as 
peers, companies with comparable projections of return on invested capital and growth rate. 
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Multiples are divided in two groups: enterprise multiples, which reflect the enterprise value 
(“EV”) of a company, and equity multiples, which express the market capitalization of a 
company. Examples of enterprise multiples include EV / EBITDA, EV / EBIT and EV / 
SALES, among others. Concerning, equity multiples, the most commonly used are the Price 
/ Earnings ratio (“PER”) and Price-to-Book value (“PBV”).  
Taking into consideration that the company doesn´t hold debt in its capital structure, 
enterprise multiples will lead to less precise estimates since the comparable companies have 
totally different capital structures – most of them use debt. Besides that, and in line with 
(Damodaran, 2009), “the cash flows to a financial service firm cannot be easily estimated, 
since items like capital expenditures, working capital and debt are not clearly defined”, as so, 
enterprise value multiples cannot be easily adapted to financial services firms. Consequently, 
equity multiples will better forecast the value of the company and the most commonly used 
are price earnings ratio (“PER”) and price to book value ratios (“PBV”). Also due to the fact 
that this valuation will be based on the FCFE, it seems a more coherent strategy to emphasize 
equity multiples as a complement to the DCF valuation. Price multiples offers several 
benefits: it’s simple and easy to implement, uses market information directly and it values a 
company relative to comparable assets. Price to book value ratio measures the equity market 
value (MV) of an asset in relation to its book value (BV). It is commonly used to value 
financial services firms such as banks and insurance companies. Price earnings multiple 
measures the current share price relatively to earnings (net income). 
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1.4 Explanation of the Model’s Variables 
1.4.1 Capital Asset Pricing Model (“CAPM”) 
The CAPM approach was developed in 1970 by William Sharp. The author identified two 
distinct types of risk when calculating the expected return of a stock: 
 Systematic risk – related with the interest rates of the country of activity and other 
events that could impact the country’s market as a whole. This risk cannot be 
diversified anyway since it is intrinsic to the economy. 
 Specific risk – can be diversified when the investor owns a portfolio of stocks. This 
type of risk is not correlated with general market variations. 
In order to calculate the expected returns of an asset, in this particular case, the cost of equity 
(Re), one should use CAPM since it is the most widely used method among academics and 
analysts. The expected return of an asset equals the rate of a risk free security plus a risk 
premium shown below: 
Equation 10 – CAPM - Re 
𝑅𝑒 = 𝑅𝑓 + 𝛽𝑒 ∗ (𝑅𝑚 − 𝑅𝑓) 
Where: 
           𝑅𝑓 =  𝑟𝑎𝑡𝑒 𝑜𝑓 𝑎𝑛 𝑖𝑛𝑣𝑒𝑠𝑡𝑚𝑒𝑛𝑡 𝑤𝑖𝑡ℎ 𝑧𝑒𝑟𝑜 𝑟𝑖𝑠𝑘 
           𝑅𝑚 − 𝑅𝑓 = 𝑒𝑞𝑢𝑖𝑡𝑦 𝑟𝑖𝑠𝑘 𝑝𝑟𝑒𝑚𝑖𝑢𝑚 
            𝛽𝑒 =  𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑟𝑖𝑠𝑘 𝑜𝑓 𝑐𝑜𝑚𝑝𝑎𝑛𝑦’ 𝑒𝑞𝑢𝑖𝑡𝑦               
It is important to stress that one should not invest in the occasion that the expected return of 
an asset doesn´t meet the required rate of return. All the variables for computing the return 
of a stock will be individually explained below, aiming to comprehend the multiple drivers 
of one of the most important assumption of this valuation – cost of equity (Re).  
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1.4.2 Risk Free 
As pointed out by (Damodaran, 2008), “we define risk in statistical terms to be the variance 
in actual returns around an expected return. The greater this variance, the more risky an 
investment is perceived to be”. So, for an investment to be risk free, the actual returns should 
always be equal to the expected return. The risk free (“Rf”) rate is defined as the rate of an 
investment with no risk, which implies that, when no variance around the expected return is 
reported, one should consider the investment as risk free, meaning that the investment will 
deliver the same return, regardless of the scenario at hand. There is an intrinsic requirement 
for an investment to be can considered risk free, which concerns its default risk1. As such, 
the securities that may be considered as risk free are government bonds2 due to the fact that 
the governments control the country’s monetary policy and currency issuing. For the 
valuation purposes, this thesis will use the risk free rate of a US ten-year treasury bond traded 
on the 28th of August 2015 – 2.2%. 
1.4.3 Equity Risk Premium 
The equity risk premium (ERP) reflects the incremental premium required by an investor 
above the risk free asset and so is defined as the spread between the historical return of a 
portfolio of stocks (market returns), usually representative of the market portfolio, over the 
historical returns of government bonds. There is a lot of debate on how to calculate the equity 
risk premium – historical ERP, as explained above, or alternative ERP regressions based on 
dividend returns. According to (Damodaran, 2002), the historical ERP is the most commonly 
used method and accordingly to his data, ERP is 5.75% for a mature market such as the S&P 
500.  
1.4.4 Country Risk Premium 
The calculation of the company’s cost of equity is based on US figures, so in order to reflect 
the additional risk present in emerging markets one should incorporate a country risk 
premium in the discount rate (cost of equity). The country risk premium for Brazil was 
obtained in Damodaran’s data sets – estimated as 2.9%. 
                                                             
1 When companies or individuals aren’t able to make the required payments of their debt. 
2 Debt issued by a country’s government. 
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1.4.5 Beta  
Beta (“”) is a company’s measure of risk, being estimated by regressing stock returns 
(ODPV3) against the market returns (IBOV), in order to observe how close the company 
stock and the market move together. This examination is undertaken as the formula suggests:  






              𝑅𝑠 = 𝑐𝑜𝑚𝑝𝑎𝑛𝑦 𝑠𝑡𝑜𝑐𝑘 𝑟𝑒𝑡𝑢𝑟𝑛𝑠  
              𝑅𝑚 = 𝑠𝑡𝑜𝑐𝑘 𝑚𝑎𝑟𝑘𝑒𝑡 𝑟𝑒𝑡𝑢𝑟𝑛𝑠 
The company’s beta estimation contemplated different time spans and has shown significant 
changeability when calculated on a daily, weekly and monthly basis (see Appendix 2). The 
beta chosen for the valuation is estimated with data from 28th of August 2010 to 28th of 
August 2015 on a weekly basis, leading to a value of 0.44. This estimation is weekly based 
because it is the intermediate time between the three time spans and also showed a more 
representative value, comparatively with the other analysis. A beta below 1 indicate that the 
stock price will be less volatile than market. In contrast, a beta above 1 represents an 
investment pattern more volatile than the market. 
1.4.6 Cost of Equity 
Cost of equity (“Re”) represents the rate of return of a shareholder’s investment. There are 
numerous ways to compute the cost of equity: CAPM, Fama-French three-factor model and 
Arbitrage Pricing Theory model (“APT”).  
The CAPM approach is the most widely used method to compute the cost of equity. 
Nevertheless, the method has been under some criticism during the last years, since Fama-
French pointed out that differences in betas from 1963 to 1990 did not explain different stock 
performances. Even though CAPM is being criticized by the investment community, it’s still 
the most used and studied method. Thus, to estimate the cost of equity of the company, this 
thesis will address the CAPM approach, but with some increments, such as inflation 
differential and country risk premium.  
Equity Valuation - OdontoPrev 
 
20  
1.4.7 Cost of Debt 
Cost of debt (“Rd”) is the current rate that a company pays to use debt financing. Cost of 
debt it is normally computed after taxes since the interest payments represent are tax-
deductibles. The financing cost gives investors an indication of the risk of a company, since 
the riskier companies are, the higher will be its cost of debt. The company doesn’t have debt 
in its capital structure so this topic will not be further discussed. 
1.4.8 Weighted Average Cost of Capital  
The weighted average cost of capital (“WACC”) is the calculation of a firm’s rate of return, 
taking into consideration the weight of each source of capital (equity and debt) in the firm’s 
value, multiplying each by the cost of each source of financing. As stated by (Damodaran, 
2007), “cost of capital is the cost of all capital invested in an enterprise”, thus calculating the 
cost of capital of a company with WACC, when the company holds different sources of 
financing, seems to be the most coherent approach. There is also the fact that WACC 
considers the adjustment for tax purposes (interest tax shield3), due to the use of debt and 
payment of interest expenses, by deducting its absolute value. The WACC is calculated 
according to the formula below: 









             𝐷 = 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑚′𝑠 𝑑𝑒𝑏𝑡     
             𝐸 = 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑚′𝑠 𝑒𝑞𝑢𝑖𝑡𝑦 
             𝑉 = 𝐷 + 𝐸 = 𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑖𝑟𝑚′𝑠 𝑓𝑖𝑛𝑎𝑛𝑐𝑖𝑛𝑔  
               𝑡 = 𝑡𝑎𝑥 𝑟𝑎𝑡𝑒 
This valuation will not calculate the WACC of the company due to the inexistence of debt in 
the capital structure, thus, the cost of capital used as a discount rate will be the cost of equity. 
                                                             
3 The reduction in income taxes which results from the tax-deductibility of interest payments. 
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1.4.9 Terminal Value 
An imperative issue regarding the DCF analysis is the unbounded life of firms. The DCF 
equation have two distinct elements in the numerator: the free cash flow forecasts and the 
terminal value. This differentiation is made due to the fact that cash flows cannot be 
accurately estimated forever. For sake of simplicity, DCF users assume that after several 
years of cash flow forecasts (terminal year), cash flows will grow forever (terminal value) at 
a constant rate. According to (Young et al., 1999), the calculation and use of the terminal 
value is the most consistent way to deal with the uncertainty of the company’s future 
performance – expressing the upcoming with a perpetuity formula. The terminal value 
represents a very important portion of the valuation since it accounts for 77% of the equity 
value estimated.  
1.4.10   Growth Rate  
Growth rate (“g”) is the rate assumed, in the perpetuity, for the terminal year of the valuation 
- year after the explicit period. For the growth rate estimation one should take into 
consideration that growth must not exceed the growth of the economy where the firm 
operates and dividend growth must increase at the same rate of other performance measures 
(Damodaran, 2002). 
In a general way, g is calculated as a product between the retention rate (“RR”) and the return 
on equity (“ROE”) as shown below: 
Equation 13 – Growth Rate Calculation 
𝑔 = 𝑅𝑅 ∗ 𝑅𝑂𝐸 
Where, 
            𝑅𝑅 = 𝑡ℎ𝑒 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑛𝑒𝑡 𝑖𝑛𝑐𝑜𝑚𝑒 𝑟𝑒𝑡𝑎𝑖𝑛𝑒𝑑 𝑏𝑦 𝑎 𝑐𝑜𝑚𝑝𝑎𝑛𝑦 𝑡𝑜 𝑓𝑖𝑛𝑎𝑛𝑐𝑒 𝑖𝑡𝑠 𝑔𝑟𝑜𝑤𝑡ℎ 
            𝑅𝑂𝐸 = 𝑛𝑒𝑡 𝑖𝑛𝑐𝑜𝑚𝑒 𝑑𝑖𝑣𝑖𝑑𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑠ℎ𝑎𝑟𝑒ℎ𝑜𝑙𝑑𝑒𝑟’𝑠 𝑒𝑞𝑢𝑖𝑡𝑦                     
The company has been distributing 100% of its net income in the last years, only retaining 
an amount for legal reserve purposes – 5% of the net income until 20% of capital value is 
reached. Post that, the growth rate will not be calculated with the formula shown above, 
thenceforth will be assumed a growth rate equal to the inflation estimations for the terminal 
year (4.5%) plus 0.5% premium, reflecting a g of 5%. 
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1.4.11    Inflation 
Inflation is the rate at which the level of prices for goods and services increases, as a result, 
the currency purchasing power is reduced. Generally, in order to keep the economy running 
efficiently, central banks restrict inflation and try to avoid deflation4. Inflation is considered 
one of the main reasons for people investing, because the value of money varies in time - 
time value of money5. 
From 1980 to 1994, Brazil suffered periods of hyperinflation due to the massive volumes of 
money creation undertaken by the central bank, aiming development projects. Nowadays, 
Brazil is showing high inflation levels (8%) but not compared with those of the last decades 
– fourteen-year period of three to four-digit annual inflation rates.  
For the purpose of this valuation, the items of the financial statements will be projected in 
nominal terms, meaning that inflation effects will be taken into consideration. The source 
used to provide the inflation estimates was the IMF databases – inflation projections, data 
from March 15th, 2015. 
Inflation Differential 
In order to adjust the cost of capital for inflation differences among U.S. and Brazil, one 
should calculate the spread between Brazilian and U.S. inflation rates. The inflation 
differential in 2015 is exceptionally high when compared with future projections so, with the 
purpose of not biasing the cost of equity and the DCF valuation, merely based on 2015 
figures, an average during a larger period (2015 to 2018) is made, giving a value of 4%. 
Table 1 - Inflation Differential between Brazil and United States (U.S.) 
Country Subject Descriptor 2015 2016 2017 2018 2019 2020 2021 
Brazil Inflation rate, end of period 8% 5% 5% 5% 5% 4% 4% 
U.S.A Inflation rate, end of period 1% 2% 3% 2% 2% 2% 2% 
BR – U.S. Differential Inflation rate (BR – U.S.) 7% 3% 2% 2% 2% 2% 2% 
 Average Differential Inflation (2015 - 2018) 4%       
                  
Source: IMF and own calculations  
                                                             
4 Decrease in the price level of goods and services (inflation rate below 0%). 
5 The money available today is worth more than the same amount in the future due to its earning capacity. 
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1.5 Valuation in emerging markets 
More than ever, capital movements between countries are becoming more liberalized, in a 
way that companies easily shift their investments from developed countries to emerging 
markets (i.e. Latin America and Asia), pursuing expansion of activities and risk 
diversification. Investing in emerging markets provide attractive returns when compared with 
mature markets, but in contrast, expose an investor or a company to additional risk, i.e. high 
inflation levels, macroeconomic volatility, political changes, war, corruption, regulatory 
changes and the lack of accounting control. The cross border investment increase has 
obligated academics and analysts to review the assumptions on the foundations of value (risk 
parameters, debt ratios and growth rates), which is forcing one to apply dynamic valuation 
models instead of the static ones – used in mature markets. 
As explained by (Goedhart et al., 2010), there are two ways to deal with the uncertainty in 
emerging markets: develop DCF scenarios or increment a country risk premium to the cost 
of capital. 
The first approach develops two different scenarios for future cash flows weighted at a certain 
probability: The positive scenario where the assumptions reflects business growth as it is 
expected, on the other hand, a negative scenario need to be valued, in order to match with the 
risks associated with emerging markets.  
The second technique adds a country risk premium to the cost of capital of the company, 
which will negatively affect the share price valuation since it increases the denominator in 
the present value calculation, thus reflecting the risks associated with emerging markets. 
This thesis addressed the second approach, adding a country risk premium, being the 
construction of scenarios considered not plausible for the valuation, as a consequence of the 
sustainable business model of the company and industry type (described in chapter 2). 
Therefore, adding a country risk premium to the calculation of the cost of equity will reflect 
the potential risks over the economy that can impact the company in the long run. 
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2 Market and Company Overview 
2.1      Market Overview 
In order to perform an accurate valuation of OdontoPrev, it´s crucial to analyze the 
environment in which the company operates, with special attention to industry growth drivers 
and risk factors of the sector. 
According to ANS6, in 2014, 50.8 million Brazilians were members of private healthcare 
plans and 21.3 million were members of dental plan benefits - 10% of the Brazilian 
population7. The dental plans market grew from 2.6 million members, in 2000, to 21.3 million 
in 2014, corresponding to a CAGR of 16.2%. In the same period, OdontoPrev achieved a 
CAGR of 20.8%, growing from 450 thousand to 6.3 million members. In 2000, the company 
had 17% market share and nowadays has 30% (see Appendix 3). A significant portion of the 
dental market is concentrated in corporate plans (as a benefit from companies to employees) 
which is a very reliable source of new members, nevertheless highly dependent on job 
creation. 
Exhibit 1 – Evolution of OdontoPrev Members vs. Dental Plans Market 
Source: OdontoPrev and ANS. 
                                                             
6 ANS is the regulator of the healthcare industry. 
7 According to IMF, Brazilian population is estimated in 203 million in 2014. 
447   
6,316   
2,603   














2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
OdontoPrev members Dental Plans Market
Equity Valuation - OdontoPrev 
 
25  
Keeping into view the Brazilian population and the percentage of the country’s population 
that owns a dental plan (11%), it is expected that dental sector continue to grow at least at 
the same pace of the last years.  
Brazil has one of the highest dentists supply in the world8, being registered 268 thousand 
professionals, equivalent to a dentist to member ratio of 1:764 comparatively with U.S. - 160 
thousand professionals for a population of 320 million, which presents a ratio of 1:2000. 
While comparing these two countries and having in mind that the U.S. is a developed country 
it’s noticeable that Brazil has an excess surplus of dentist professionals. Even though the 
existence of numerous professionals in the sector, there is a huge gap between supply and 
demand for this service, since only 11% of the population has access to dental care. This 
occurred due to the lack of efficient companies providing the service, resulting in higher 
prices – not affordable for the population in general. As opposed to the healthcare industry, 
where individuals have the government healthcare system, the dental care was only fulfilled 
by dentists, without the support of a management team and financial partner, being extremely 
unaffordable for the population. This business model was directed to the segment of the 
population who could afford higher prices and prompt payment. This fact allowed for the 
provision of highly technical and scientifically advanced dental care procedures using refined 
and exclusive resources. 
The lack of access to dental care created an opportunity for dental plan companies to 
penetrate the market, supported with capital and management know-how. As a result, after 
the second half of the 1990s, the dental plan sector grew consistently due to several factors: 
 Structural disparity between the supply and demand of the service; 
 Lack of public service alternative; 
 Inclusion of dental plans in corporation’s benefits for the employee; 
 Interest from new distribution channels; 
 Reforms made by the regulator of the sector (ANS); 
 
                                                             
8 Source: Conselho Federal de Odontologia – Brasil, Julho 2015. 
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2.2     Risk Factors 
There are two types of risk factors to be pointed out: risks related to Brazil (macroeconomic 
events) and risks related to the dental plan sector. While analyzing an emerging market, it’s 
important to be aware of all macroeconomic and political risks that could harm the company. 
The Brazilian government exercises significant influence over the economy and so, there are 
several variables that could negatively affect the company: 
 Unemployment 
 Inflation 
 Fluctuation of interest rates 
 Volatility in the exchange rate (mostly, BRL - USD) 
Those negative variables can impact catastrophically the Brazilian economy in a sense that 
they can restrict the production of the country (GDP), raise the prices of goods and services 
at an internal and external level, leading to a reduction in the OdontoPrev’s dental plan sale 
and ultimately impact the company in the stock market. Dental care companies operate in the 
insurance business and in order to be profitable, have to accurately estimate and control costs: 
the company increases monthly fees to offset future cost increases. Companies have been 
reducing its dependence on external brokers, since they work without exclusivity and have 
an excessive bargaining power. Companies must undergo new distribution channels, such as 
bancassurance9, direct sales and online sales to create a better dynamic of customer addition, 
leading to a better quality of sales, with lower commissioning and higher margins. The dental 
care industry could be adversely affected by new government regulation and also in the case 
where government decides to establish a subsided dental care system itself. Nevertheless, the 
risk pattern of dental care is different from medical care. Medical care costs increase with the 
aging of the population and with the introduction of new and costlier equipment. Inversely 
related, dental care costs are higher in the beginning of the contract period, since dental 
treatments had never been made but after this initial peak, the cost per member decreases 
until it reaches a maintenance level that tends to remain stable, independently of the 
member’s age (see Appendix 4).
                                                             
9 Bancassurance is a financial agreement between a bank and an insurance company, allowing the insurance 
company to sell its products to the bank's client base. 
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2.3      Company Background 
OdontoPrev was established in 1987, when a group of dentists identified an opportunity in 
providing dental care for corporate clients. In August 1998, a Private Equity firm acquired 
control of OdontoPrev, highly contributing to the strategic leadership positioning of the 
company, current market leader in the sector and responsible for the development of new 
innovative corporate governance practices in the Healthcare sector. In December 2006, the 
company went public through an Initial Public Offering (IPO), raising 171,411 BRL net of 
placement expenses. Overall, 18,643,973 shares were sold at 28 BRL per share, totalling 522 
million BRL - at this time the free float of the company was 84.2%. The IPO and the 
companies that OdontoPrev bought contributed to a member increase of 1.5 million (2006) 
to 6.2 million (2013). After the IPO, OdontoPrev bought several companies (inorganic 
growth10), mainly small competitors and other companies that presented high potential of 
synergy, generating competitive advantages, i.e. Easy, a supplier of medical software 
provided a helpful monitoring system that assess the quality of the service provided and 
mitigates fraudulent activity on the dentist and customer side, resulting in a lower DLR11.  




                                                                                                                        
 
  
 Source:  OdontoPrev Corporate Presentation September 2015. 
                                                             
10 A growth in the operations of a business, due to mergers or takeovers, rather than an increase in the 
company’s own business activity. 
11
 Dental loss ratio (DLR) is the ratio of total losses incurred in claims divided by the total premiums earned. 
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In October 2009, OdontoPrev celebrated an agreement with Bradesco Dental S.A to merge 
the activities of both companies and two months later OdontoPrev was a fully integrated 
subsidiary of Bradesco S.A (see company structure below): 
Exhibit 3 – Company Structure: Owners and Subsidiaries 
                                                  1                                                                       2                        
 
Source: OdontoPrev; 1 – Company Shares; 2 – Minority Shareholders 
In June 2013, OdontoPrev signed a contract with Banco do Brasil Seguros Participações S.A 
for an Association through a separate vehicle - Brasildental Operadora de Planos 
Odontológicos S.A, with the objective of distribute and commercialize dental plans, 
exclusively under the channel and brand name of Banco do Brasil, during 20 years, with the 
option of renewal for the same period. This association will allow OdontoPrev to better reach 
SME’s and individual contracts, which are the operating segments that the company as lack 
of access. Banco do Brasil has 60 million clients and those are different target clients while 
comparing with Bradesco. 
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2.4     Company Analysis 
OdontoPrev is a dental care operator that provides dental benefit plans for three main 
segments: corporate, small and medium enterprises (“SME”) and individuals. In 
compensation for the dental service provided, the company charges a monthly fee, depending 
on the coverage of the plan. In December 2014, the company had 6.3 million clients, from 
which 5.1 million were corporate clients; 800 thousand SME contracts and 400 thousand 
were individuals. The member’s portfolio of the company divided by segment is exhibited 
below. 
Exhibit 4 - Evolution of Members by Segment 
 







 Source: OdontoPrev Corporate Presentation of September 2015  
OdontoPrev is the market leader of the dental care sector in Latin America, where its clients 
enjoy differentiated health solutions provided by an extremely specialized network of 25,000 
dentists. OdontoPrev operate two distinct types of plans: pre-paid plans and post-paid plans. 
In the first and most chosen payment modality, the type of coverage and the monthly payment 
are previously defined. The customer receives the dental care service covered by the plan 
chosen through the accredited network, without any additional disbursement. In the second 
model, the customer chooses the surgeon and the clinic where wants to be treated, but has to 
pay directly to the dentist and subsequently ask for the reimbursement, under the limits of 
the contract. OdontoPrev also provide some treatments in company-owned units. 
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2.5     Company’s Stock Performance 
OdontoPrev is listed in the BM&FBovespa12 (Ticker: ODPV3), being a component of Brazil 
IbrX 100 index, which is designed to measure average stock performance of the 100 most 
traded stocks of the Brazilian stock market. The company is part of the most demanding 
listing segment in Brazil (also called Novo Mercado), founded in 2000, aiming companies to 
voluntarily assume corporate governance levels above the requirements. For instance, the 
minimum requirement for Dividend Pay-out Ratio (“DPR”) is 25%, meanwhile OdontoPrev 
distributes 100% of the net income to shareholders. The company’s free float represents 
47.6% of total shares, dispersed in 33 countries, 50.01% belongs to Bradesco, the controlling 
shareholder, and the remaining amount is treasury (see Appendix 5). Bradesco is the second 
largest private bank in Brazil and is considered a strong partner of OdontoPrev since the bank 
has a large amount of clients (more than 80 million) and a strong reputation with them. The 
company had been constantly beating the Bovespa index since 2009 and the total shareholder 
remuneration in 2014 was 4.5%, represented by a share variation of 0.3% and 4.2% in 
dividends and interest on capital. 







Source: OdontoPrev Corporate Presentation September 2015.            
                                                             
12 Sao Paulo stock exchange, former Bovespa (founded in 1890), has merged with the Brazil Mercantile and 
Futures Exchange in 2008, creating BM&F Bovespa. 
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2.6      Company Strategy 
The strategy of OdontoPrev is to lead the consolidation of the healthcare sector in Brazil, by 
providing dental care treatment to the population at a fair price, or as stated in their mission: 
“To become a major link between society and dentistry, adding value to this relationship by 
providing excellent services to both”. 
The mission of the company will be achieved through the efforts of an experienced and 
specialized management team, who have a deep understanding of the Brazilian dental care 
market, by maximizing the quality and reliability of the service given. OdontoPrev is 
constantly seeking economies of scale to improve cost efficiency, placing though the product 
at a fair price.  
There are multiple growth vectors that allow this strategy to happen:  
 Inertial growth: the expansion of corporate clients’ workforce represents a chance to 
growth, since a higher number of members will be reached without cost of capture; 
 Organic growth: capturing new clients with the effort of sales and marketing teams; 
 Inorganic growth: by acquiring companies seeking potential synergies whereas could 
increase growth and generate higher results; 
 Commercial partnerships and new distribution channels: strategic partnerships such 
as bancassurance is the optimal way to access unexplored markets with lower 
penetration, providing higher growth potential, namely SME’s and individuals; 
Those growth vectors are consistent with the distribution channels used by the company, 
allowing for the provision of an efficient and diversified distribution channel network: 
 Internal sales team; 
 Online sale; 
 Independent brokers; 
 Cross sale with medical plans (through partnerships with other operators); 
 Bancassurance (Bradesco & Banco do Brasil); 
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2.7      Competitive Advantages 
The dental service provided by OdontoPrev is recognized for its reliability by more than 
6,000 Brazilian and multinational corporate clients, such as Ambev, Globo, MacDonald’s and 
Coca Cola. The diversity of services offered, carefully segmented for each group of clients 
plus the multiple and strategic distribution channels enable the company to grow sustainably. 
Besides that, OdontoPrev is proprietary of an IT platform, allowing the company to: 
 Manage the logistics and relations with dentists; 
 Monitor the performance of each dentist; 
 Monitor the oral health of their associates and their relations with the company; 
 Adopt a pro-active approach for managing the clinical and behavioural risk of dentists 
and members; 
 Monitor the quality of the services provided; 
The IT platform owned by the company has proven to be a good competitive advantage, 
resulting in a significant decrease in the cost of services, by reducing the service claims while 
increasing the quality of the service provided due to the higher monitoring and control of the 
dentist’s skills and member’s claims. 
The management team have demonstrated a deep knowledge of the market. Most of the 
managers are dental plan specialists, with expertise in the dental sector for decades, having 
the awareness to design the product to fit different client’s needs. Concluding, actions taken 
in the past and measures implemented recently, alongside with the multiple competitive 
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2.8     Competitor Analysis 
The dental care sector in Brazil is highly fragmented, facing significant rivalry from new and 
existing competitors. In the last 3 years, companies engaged in an irrational fierce 
competition fighting for the same client, pushing towards a price war scenario. According to 
an Industry Outlook for 2015, done by Votorantim corretora13: “In 2012, the difference 
between the average maximum and minimum prices was R$ 6.90. In June 2014, this gap 
narrowed to R$ 3.60, showing a more competitive environment among the main players”. 
The war on prices ended last year due to the unaffordable costs that companies had to bear, 
as a consequence of that strategy. 
As mentioned before, 21.3 million Brazilians own a dental plan and OdontoPrev assists 6.3 
million, representing 30% of the market. One crucial fact that explains the leadership position 
of the company is the degree of specialization in the dental care sector, comparatively to its 
peers, which are mainly healthcare operators – cross-selling healthcare plans with dental 
plans. Thus, the company provides a differentiated service and operates throughout the entire 
Brazilian territory.  
The company operates in a competitive market where companies offer dental care plans with 
comparable benefits, such as healthcare companies, insurance companies and hospitals. The 
sector has 1,425 dental care active providers and according to ANS, the dental plan sector is 
going through a period of consolidation14. Most of the companies operating in the dental plan 
sector are specialized in medical care but also sell dental plans (cross selling), i.e. Amil, 
which was bought by UnitedHealthcare15, has 10% of the market share. Amil is the biggest 
Brazilian company in the healthcare sector, specialized in all type of medical services, dental 
benefits included. Other significant players are: InterOdonto (5%), SulAmérica, MetLife and 
Caixa all with 3% each (see Appendix 6). 
                                                             
13 
Votorantim Corretora is a Brazilian Investment bank acting mostly as a brokerage firm. 
14 
A stage in the life of an industry in which its components start merging to form fewer components. 
15 UnitedHealthcare is one of the biggest medical insurance companies across the US and internationally. 




In this chapter, assumptions and forecasts that ultimately lead to the estimated value per share 
will be presented. Each variable of the income statement will be defined, analyzed and 
projected for future periods (explicit period16 and terminal value), the same will be done to 
the cost of capital and the determinants of its calculation. All the assumptions are estimates 
of the IMF database projections and own analysis of company historical performance. 
Furthermore, as introduced previously, two methods were used to value the company on the 














                                                             
16 The time span considered for the valuation (2016 -2021) 
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3.1     Net Operating Revenue 
The company valuation strongly depends on the revenues forecast, since the vast majority of 
the items in the income statement are projected as a percentage of net operating revenue. 
According to (Stowe et al., 2007), a top-down forecasting approach should be followed, 
starting with international and national macroeconomic forecasts to reach industry and asset 
forecast, in contrast with the bottom-up forecasting approach, which is based on asset 
forecasts rather than macroeconomic environment – subject to inconsistent problems, such 
as different inflation assumptions undertaken by different analysts.  
OdontoPrev offers dental plan benefits to three different segments (corporate, SME’s and 
individuals), each of them with different growth standards and pricing strategies – considered 
relevant to forecast revenues for the explicit period. Since the company only started to 
disclose their revenues by type of segment in the first quarter of 2015 and yet has not provided 
any historical background, this Thesis will not display the breakdown of revenues by 
segment. Hence, the revenues estimation was addressed using global values, in mind 
revenues historical growth. 
To better understand the growth drivers of sales, a breakdown between average ticket and 
average members is made: average ticket refers to the price that members pay per month 
(R$/Live/Month) and average members stand for the amount of contracts that a company 
owns within one year, on average. For the average ticket - as a pricing strategy of the 
company - a growth rate marginally beyond inflation is assumed, as mentioned in the 
conference call of the company in first quarter of 2015. Thus, based on IMF inflation 
estimates and historical pricing policy of the company, an average ticket growth weighted at 
90% of the estimated inflation is assumed, revealing a 4% ticket growth per year. The average 
members forecast is based on the historical average growth between 2012 and 2015 - a period 
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After estimating the average members and average ticket, a forecast of the NOR for the 
explicit period is the final outcome, reaching to R$ 2.25 billion in 2021, as exhibited below: 








 Source: OdontoPrev and own calculations  
The average ticket for 2015 is calculated taking into consideration the average ticket reported 
in the 1st half of 2015, 16.64 BRL, which is assumed to remain the same value for the 2nd half 
of the year. Average members in 2015 are estimated to grow 3% over 2014.  
The combined effect of the revenue drivers (average ticket and average members) results in 
a growth rate of 10% of the net operating revenue (NOR) during the explicit period – except 
for 2015 and 2016 which is 12%, as shown in the figure below: 
Exhibit 7 – Historical and Forecasted NOR growth (%) vs. Brazilian GDP (%), at current prices 
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3.2     Cost of Services 
This thesis calculated the cost of services as a percentage of NOR, taking into consideration 
the top-down forecasting approach and following (Goedhart et al., 2010), who recommends 
operating expenses, such as cost of services, selling and administrative expenses and other 
operating expenses to be forecasted as a percentage of net operating revenue. Cost of services 
is the cost of providing the treatment to the clients of the company and it’s composed by:  
 Healthcare claims (87% of cost of services) – represents the amount paid to the 
network of dentists for treatment purposes. In the past years, this item has shown 
variability in the amount of claims. The company closely monitors its contracts to 
mitigate future risks and currently considers that a claim ratio of up to 60% permits a 
margin that supports the company’s administrative expenses; 
 Payroll charges on services (6% of cost of services) – social security charges on the 
account of the employee. Since 2010, the company is facing a judicial process 
claiming allegedly unpaid extraordinary expenses. OdontoPrev is holding the position 
that the network of dental practitioners’ social security taxation is not imputable to 
the company, but rather to the dental offices, since OdontoPrev simply aims to act as 
an intermediate; 
 Dental materials (1% of cost of services) – provided to the network of dental clinics 
to ensure the maximum quality of the treatment; 
 Other expenses (6% of cost of services) – composed by IBNR and other expenses. 
IBNR stands for incurred but not reported claims reserve. This item refers to claims 
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Cost of services represent the percentage of NOR that turns into cost for the company and 
the major growth driver of this item is the healthcare claims. Cost of services is estimated as 
a whole, in a simplistic way, since the other components did not represent a significant weight 
in this item, as so, they were not projected for the explicit period. In the last 8 years, cost of 
services had fluctuated between 43% and 51%, as a percentage of NOR. 
 







Source: OdontoPrev and own calculations. 
Cost of services represented 47% of NOR in the first half of 2015, which is in line in the last 
two years, thus it’s assumed that figure for 2015. Moreover, for the explicit period, cost of 
services is projected to represent 46% of NOR, displaying a reduction in the DLR, as result 
of the management team’s effort to mitigate the fraud and improve the quality of the service 
given (see Appendix 8). This assumption is also supported by the rational stability of the 
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3.3      Selling Expenses 
Selling Expenses comprise the amount of commissions paid to brokers, who were responsible 
for the dental plan sale. Generally, these expenses follow the growth pattern of revenues, but 
not necessarily at the same pace, given that the company is changing its distribution channels 
in order to increase its margin and reduce the dependence on external brokers. 
The company relies on many sources to distribute its service, such as external brokers, own 
sales team and retail stores. However, this year the company launched a new and more 
efficient distribution channel: the online selling, which will help the company to reach new 
clients with zero commissioning, resulting in an overall lower cost. In addition, 
bancassurance is becoming a more prominent and strategic distribution channel, resulting in 
a reduction of the selling commission from 17.5% to 12.5%, in comparison with retail store 
channels and external brokers. As a result, a reduction of the selling expenses’s weight on 
NOR is forecasted for future periods. 
In the last four years, selling expenses presented a constant performance profile, ranging 
between 9% and 9.5% of NOR. After the implementation of distribution channel structural 
changes, one may assume a growth for this item in line with sales, but must also take into 
consideration the efficiency of the new distribution channels. Thus, for the projections of 
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3.4      Other Items 
Administrative Expenses  
The most significant items of the administrative expenses are personnel costs, rentals and 
third parties services. This item will remain stable over the years, as a percentage of Net 
Operating Revenues because as the activity of the company expands, more personnel and 
third parties services are needed. For that, and based on historical analysis, 14% of the NOR 
is projected for all the explicit period. 
Other Operating Expenses 
Other operating expenses comprise 3 main items: allowance for doubtful receivables, stock 
option and profit sharing. These expenses are the less relevant costs of the company since it 
accounts for only 3.8% of NOR. Allowance for doubtful receivables is the most significant 
line of this item, representing 2.8% of the NOR in the last 4 years, on average. Since the 
company is changing its distribution channels to more reliable ones, it’s expected a slightly 
decrease for the explicit period, as so it was assumed 2.5% onwards. The reminiscent items 
(stock option and profit sharing) were projected for 2015 onwards as the average between 
2011 and 2014, being 0.5% and 0.6%, respectively. 
Net Financial Income 
Net financial income comprises three items: financial income, financial expenses and interest 
on capital (“IOC”). This line of the income statement represented 1.2% of NOR, on average, 
relatively to 2011, 2012, 2013, and was 1.3% in 2014. For the financial income and financial 
expenses, it is assumed a moving average of the last 4 years, for the explicit period. Relatively 
to interest on capital, it is estimated as a percentage of the company’s capital, though being 
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Current and Deferred Tax 
Current tax represented 28.8% of Earnings before taxes (“EBT”) on average, concerning 
2011, 2012, 2013, being 28.9% in 2014, so the estimated current tax for the explicit period 
was 28.9%. A deferred tax refers to tax paid but not yet recognized in the income statement, 
so the taxes related to equity in subsidiaries (Brasildental) are deducted in this account 
preventing tax double counting. This thesis is assuming that there will be no significant 
changes in the corporate taxation policy in Brazil. 
Cash 
Cash is one item of the balance sheet that comprises cash, bank accounts and marketable 
securities, such as government bonds. This value was 265 million at the end of 2014. Cash is 
estimated by projecting the cash flow statement of the company for 2015. The final cash for 
the end of 2015 is estimated as R$ 315.9 million, and it is calculated accordingly the table 
shown below. 
Table 2 – Cash – Cash Flow Statement of 2015 
CF Statement (R$ thousand)  2015 
Net Income       235,111    
Equity in subsidiaries -         5,592    
Stock Option plan           8,419    
Depreciation           7,500    
Reserve for contingencies liabilities         53,314    
CF Operations         63,641    
Capex -       16,000    
INV. NWC -       16,807    
DIV -     181,314    
JCP -       34,370    
Initial cash (2015)       265,708    
Final Cash       315,968    
Increase/Decrease         50,260    
    
Source: OdontoPrev and own calculations. 
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3.5     Equity in Subsidiaries 
This item refers to all the entities over which OdontoPrev has significant influence or shares 
the control of the operational and financial policies, being valued through the equity method. 
Brasildental was established in 2013 aiming to distribute OdontoPrev’s dental plan, 
conjointly with Banco do Brasil, through the bancassurance channel and started the 
operations in the beginning of 2015. OdontoPrev holds a 25% stake of this venture, being 
recognized as equity in subsidiaries in the income statement. In order to accurately estimate 
the ability of this vehicle to generate growth, a valuation of this joint venture is made 
separately and step by step.  
The revenues of this vehicle are breakdown in two distinct groups: Banco do Brasil 
employees and Banco do Brasil – Distribution channel. These groups have a different 
average ticket, the first is considered 11 BRL per month, since it is directed to employees of 
Banco do Brasil - and then a price discount is applied. For the second group, an average 
ticket of 22.54 is estimated as a weighted average between SME’s ticket (60%) and 
Individuals (40%), using data of the first half of the year, resulting in a ticket of 23.44 for the 
end of the year.  The starting point to get an estimation of the average members is the number 
of clients that Banco do Brasil has – 60 million. For the first year, it is estimated the capture 
of 0.5% of clients of the bank, which is 300 thousand members for 2015. Regarding the 
growth considered during the explicit period, by 2021, 3.5% of the clients of the bank will 
have subscribed a dental plan (see Appendix 9). 
All the costs of this joint venture are projected at the same percentage of NOR in an identical 
way as the forecasted income statement – except selling expenses, where it’s expected to 
decrease due to the efficiency of the channel – low commissioning costs. As so, there is 
projected a growth of this line but only 75% of what is estimated for the income statement of 
the company as a whole. After estimating the income statement of the joint venture, and when 
the net income is reached, OdontoPrev will receive 25% of the dividends distributed, after 
the reinvestment needs were fulfilled. The item equity in subsidiaries is accounted in the 
income statement and thus is subject to taxes. Since this joint venture had been taxed 
previously, the value calculated for tax purposes, related with Brasildenta, will be deducted 
in deferred tax account.
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3.6     CAPEX 
Capital expenditures (“CAPEX”) are the funds used by the company to invest in physical 
assets, such as properties, buildings and equipment, denominated as maintenance CAPEX, 
or to expand its activity by undertaking new projects (i.e. Opening a factory in a new market) 
– expansion CAPEX. The CAPEX outlay is interrelated with the industry where the company 
operates, being production, oil exploration, manufacturing and utilities where capital 
intensiveness is higher. OdontoPrev’ business do not need high capital expenditure to 
maintain its activity due to their position on the value chain, acting as a broker between 
customers and dentists, though the only physical assets the company owns are its 
headquarters, equipment and a pair of dental clinics.  
3.7      Depreciation 
Depreciation is the method of allocating the cost of a tangible asset during its useful life. 
Companies depreciate its assets for both accounting and tax purposes: in accounting, it is 
employed to match the expense related with an asset, to the income which that asset helps 
the company generate; for tax purposes, the company can deduct this cost of tangible assets 
as an expense, reducing the taxable base. Sometimes, companies report the life period of an 
asset differently for tax purposes, perhaps to show a better performance of the company in a 
specific period, however, companies must depreciate assets in accordance with IFRS rules, 
taking into consideration how long it will last. 
In the industry where OdontoPrev operates (dental insurance), companies usually do not hold 
large amounts of physical assets in their Balance sheets, mainly because they operate in the 
tertiary sector (services), as so they do not need the same amount of fixed assets 
comparatively to a company in the production or infrastructure sector. OdontoPrev’s 
percentage of long-term assets in total assets is 14%, which demonstrate the non-dependence 
on physical assets to maintain and develop the activity. As a consequence, it is expected a 
low depreciation cost, proportionally, due to the little amount of physical assets to depreciate. 
Depreciation costs are forecasted for the explicit period as a percentage of gross PPE 
(property, plant & equipment), since this account has shown a consistent trend in the last 4 
years, between 28% and 35%. In that way, it was assumed a depreciation growth at 30% of 
the gross PPE. For the estimations of CAPEX and Depreciations (see Appendix 10). 
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3.8     Net Working Capital 
Working capital measures the ability of a company to pay its short-term liabilities with short-
term assets, without using other sources of financing. This analysis evaluates the company’s 
health by looking at its short-term financial efficiency: If the company fails to accomplish its 
obligations towards creditors, then will be in trouble because will have to fall back upon in 
more expensive sources of credit than if had prepared itself for this situation. Net working 
capital (“NWC”) calculation it’s a crucial step of the valuation for the reason that it has to be 
subtracted in the FCFE formula. An increase in NWC is considered a negative cash flow, 
because it’s an increasing requirement of capital for the operations of the company so it is 
not available to equity. The way to compute NWC is shown below: 
Equation 14 – Net Working Capital Calculation 
𝑁𝑒𝑡 𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 = 𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝐴𝑠𝑠𝑒𝑡𝑠 − 𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 
Or, 
𝑁𝑒𝑡 𝑊𝑜𝑟𝑘𝑖𝑛𝑔 𝐶𝑎𝑝𝑖𝑡𝑎𝑙 = 𝐴𝑐𝑐𝑜𝑢𝑛𝑡𝑠 𝑅𝑒𝑐𝑒𝑖𝑣𝑎𝑏𝑙𝑒 − 𝐴𝑐𝑐𝑜𝑢𝑛𝑡𝑠 𝑃𝑎𝑦𝑎𝑏𝑙𝑒 + 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 
Where, 




             𝐷𝑆𝑂 = 𝑑𝑎𝑦𝑠 𝑠𝑎𝑙𝑒𝑠 𝑜𝑢𝑡𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔      




            𝐷𝑃𝑂 = 𝑑𝑎𝑦𝑠 𝑝𝑎𝑦𝑎𝑏𝑙𝑒 𝑜𝑢𝑡𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔 




            𝐷𝑆𝐼 = 𝑑𝑎𝑦𝑠 𝑠𝑎𝑙𝑒𝑠 𝑖𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦 
It is assumed for the explicit period that the DSO, DPO and DSI remain the same figures of 
2015. These ratios were calculated for 2015 as the average of the last four years, therefore it 
is projected that value for 2015 onwards. In the FCFE calculation, one should subtract the 
variation of NWC (see Appendix 11). 
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3.9      DCF Valuation 
The DCF valuation is the sum and culmination of all the assumptions explained above. The 
income statement is forecasted until 2021, same as depreciation, CAPEX and NWC. The 
FCFE will be projected for the explicit period and discounted at the cost of equity, calculated 
according the CAPM approach, adding a country risk premium and an inflation differential 
as explained above. The table with the cost of equity calculations is shown above: 
Table 3 - Cost of Capital (Re) Calculation 
CAPM 2014 2015 2016 2017 2018 2019 2020 2021 
Cost of Equity - Re 13.1% 15.0% 10.8% 9.8% 9.7% 9.8% 9.7% 9.7% 
Rf 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 
Equity Risk Premium (ERP)  5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 5.8% 
Beta 0.437 0.437 0.437 0.437 0.437 0.437 0.437 0.437 
Country Risk Premium 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 
Inflation Dif 5.5% 7.5% 3.2% 2.3% 2.2% 2.3% 2.2% 2.2% 
Average Differential Inflation (2015 - 2018) 3.8%       
                  
         
CAPM 2015        
Cost of Equity - Re 11.3%        
Rf 2.2%        
ERP (Rm-Rf)  5.8%        
Beta 0.44        
Country Risk Premium 2.9%        
Average Differential Inflation (2015-2018) 3.8%        
           
Source: Own calculation 
Cost of equity for 2015 is calculated starting with the Rf rate, adding next the country risk 
premium and the average inflation differential, subsequently is added a premium resulting 
from beta times ERP. The CAPM approach outcomes a cost of equity of 11.3%, reflecting 
the rate demanded for the shareholder’s investment. 
Starting with the net income projections (see Appendix 12), the free cash flows to equity are 
calculated according to the equation 5, presented in the literature review. After that, these 
cash flows are discounted for 2015 at the cost of equity, during the explicit period and for the 
terminal value, it is assumed a spread between cost of equity and the growth rate as a discount 
factor, in perpetuity. Subsequently, the terminal value is discounted back from 2021 to 2015.  
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After discounting the cash flows, correspondent to the enterprise value of the company, the 
net debt (debt – cash) should added, to reach the equity value of the company.        
Table 4 – FCFE and Equity Value 
FCFE (R$ thousand)  2016 2017 2018 2019 2020  2021 (TV) 
Net Income 280.5 314.9 354.1 405.7 448.6  494.7 
        
- CAPEX -17.6 -19.4 -21.3 -23.4 -25.8  -28.3 
+ Depreciation 7.9 8.3 8.7 9.1 9.6  10.1 
- Change in NWC -11.3 -9.3 -10.1 -11.0 -12.0  -13.2 
        
FCFE 259.5 294.5 331.4 380.4 420.4  463.2 
        
Re 11.3% 11.3% 11.3% 11.3% 11.3%  11.3% 
Year 1 2 3 4 5  6 
Discount factor 0.898 0.807 0.725 0.651 0.585  15.775 
g       5.0% 
        
Discounted FCFE            233              238            240              248              246      
Terminal Value (TV)              7,671    
PV (TV)              4,030    
                
        
Enterprise Value         5,234          
Net Debt -          316          
Equity Value         5,550          
        
Price (31-12-15)         10.45          
 Price (28-08-15)            9.79          
 Up/Downside Potential  6.7%       
        
Number of Shares     531,295          
 Treasury Shares          3,918          
                
Source: Own calculations 
The enterprise value (“EV”) of the company is R$ 5,234 million and net debt is R$ (316) 
million – the company structure is debt free, so this value refers to cash. By subtracting net 
debt to EV, one obtained the equity value of the company - R$ 5,550 million. The equity 
value is then divided by the number of shares available for sale (531 million), giving a price 
per share of R$ 10.45, on the 31th of December 2015. The price per share reflects an upside 
potential of 6.7% when compared with the value of the share on the 28th of August 2015. 
After examining the estimated price per share of OdontoPrev, one should recommend 
investors to hold the investment. 
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3.10  Sensitivity Analysis 
After the DCF valuation and in order to observe what would be the value of the company 
when key variables change, such as cost of capital and the growth rate, a sensitivity analysis 
is implemented. These variables were stressed to a plus/minus 1% test for each side and the 
results shown a price range between R$ 9.36 and R$ 11.98. The sensitivity analysis is shown 
below: 
Table 5 – Sensitivity Analysis 
Price -1% -0.5% Re +0.5% 1% 
Dec-2015   10.45    10.3% 10.8% 11.3% 11.8% 12.3% 
-1% 4.0% 9.37 9.37 9.36 9.36 9.36 
-0.5% 4.5% 9.88 9.88 9.87 9.87 9.87 
g 5.0% 10.47 10.47 10.45 10.46 10.46 
+0.5% 5.5% 11.16 11.16 11.16 11.15 11.15 
1% 6.0% 11.98 11.98 11.98 11.98 11.97 
              
Source: Own calculations 
The sensitivity analysis provided an empirical support for the recommendation previously 
given – hold. In that sense, on the worst case scenario, an investor will lose 12% of the value 
invested and in the best case view will earn 14% of that amount. This is only valid on the 
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3.11 Relative Valuation 
This valuation exercise will use equity multiples rather than enterprise multiples, mainly for 
two reasons: DCF model chosen – FCFE; sector of activity – insurance firm. Enterprise 
multiples lead to value distortions, due to differences in capital structures, i.e. OdontoPrev 
do not has debt so will not be fairly compared against a leveraged company. The equity 
multiples chosen to undertake this valuation are PBV and PER since these ratios are the most 
used ones across equity multiples and also lead to better value estimations in financial 
services firms.  
Since OdontoPrev is the market leader in its sector, there is no company with similar 
performance in the Brazilian market. As such, to better reflect the company’s performance, 
the construction of two peer groups is necessary – one composed by South American 
companies and another by international ones. The first group consisted of dental care 
providers in Brazil. OdontoPrev, SulAmérica, Dasa and Qualicorp are the selected companies 
given this criterion. On a first stage selection, SulAmérica and Dasa are excluded, since they 
presented too much leveraged to be considered comparable to OdontoPrev – both D / V ratios 
are higher than 30%. Though, using Qualicorp as a peer and after analyzing the PER and 
PBV ratios, the following prices are obtained: 
Table 6 – National Peer Group 
National Peer Group PER FY1 PBV ROE EV (R$ thousand) 
OdontoPrev                       24.14                           8.62                  0.31      5,203,475    
Qualicorp                       16.56                           2.27                  0.06      5,012,569    
Average                       20.35                           5.45                  0.19     
     
OdontoPrev Net Income (2015) Book value   
                       235.1                         495.1      
OdontoPrev Price (R$) Price (R$)    
                         9.00                           5.07      
          
Source: Bloomberg Terminal and own calculations. 
According to the Price Earnings Ratio (PER), the value per share of the company is R$ 9 and 
the PBR is R$ 5.07. The latter result reflects the strong influence of the PBV of Qualicorp in 
this analysis. This may signal an overvaluation of OdontoPrev since its PBV is 4 times higher 
Qualicorp’s indicator of 2.27. The multiple used to support the DCF Valuation is the PER 
for 2015 due to proximity of the ratios of the two companies. 
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For the construction of the international peer group, companies with operations in the U.S. 
were taken into account – this is because this marketplace is a reference for the Brazilian 
economy and has a wide variety of healthcare firms, with stronger operations and financial 
performance when compared to OdontoPrev. Global players such as UnitedHealthcare, 
Aetna, Cigna and Centene were included. The peers chosen for the comparison were selected 
based on the weight of debt in its capital structure – a maximum limit of 15% in their D / V 
ratio was established as an acceptance criterion. The results are the following: 
Table 7– International Peer Group 
International Peer Group PER FY1 PBR ROE EV (R$ thousand) 
OdontoPrev 24.14 8.62 31.4% 5,203,475 
UnitedHealthcare Group 19.16 3.47 18.5% 434,371,951 
Aetna Inc 15.68 2.68 15.5% 155,962,526 
Cigna Corp 16.66 3.26 19.1% 133,867,331 
Centene Corp 24.63 4.30 19.9% 26,269,469 
Average 20.05 4.47 20.9%  
Median 19.16 3.47 19.1%  
     
 Net Income (2015) Book Value    
 235.1 495.7   
 Price (R$) Price (R$)   
 8.87 4.17   
          
Source: Bloomberg Terminal and own calculations. 
A more consistent relative valuation is registered with the PER indicator, as shown by the 
price per share - R$ 8.87. The PBV, on the other hand, is even smaller than the one recorded 
in the national peer group, which may indicate not only that the Brazilian stock market is 
overvalued as a whole when compared with mature markets, but also that OdontoPrev’s 
leadership position and the constant good performance in the stock market (outperform), 
strongly bias the asset comparison with other peers. Before presenting the conclusions 
reached, it is important to mention that the relative valuation exercise is used in this thesis to 
monitor the DCF approach and, as such, the results of the PER will only be a complement to 
the DCF analysis. The conclusions of this analysis are strongly influenced by OdontoPrev’s 
leading position in Brazil and consequent overvalued indicators – when compared with 
similar companies, with national and international operations, the results indicate that a 
market leader in its sector will seem overvalued.




4. Investment Bank Report Comparison 
OdontoPrev has a strong analyst coverage of 13 investment banks, including not only global 
players such as J.P Morgan, Morgan Stanley, HSBC and Santander but also local based 
banks: BTG Pactual, Itaú BBA and Votorantim Corretora. The analyst chosen for the 
valuation comparison is Thiago Macruz from Itaú BBA and the research report dates to the 
20th of July 2015, being the estimated fair value of OdontoPrev on December 2015 of R$ 
10.3 The value of the company was estimated according to the DDM approach, during an 
explicit period of 12 years (2016 – 2028), significantly higher than the one that has been 
assumed for OdontoPrev’s valuation – 5 years for the explicit period and one year as a 
terminal value. The key valuation figures comparison is presented below: 
Table 8 – Comparison of the Key Variables Estimations  
Analyst Estimates (R$ million) 2015 2016 2017 2018 2019 
NOR 1210 1377 1563 1761 1967 
NOR Growth  14% 14% 13% 12% 
EBITDA 333 400 464 582 652 
Net Income 233 280 316 393 442 
Net Debt -338 -343 -349 -356 -365 
PER 25 21 19 15 13 
PBV 8 8 8 8 8 
      
OdontoPrev Estimates (R$ million) 2015 2016 2017 2018 2019 
NOR 1258 1414 1555 1707 1874 
NOR Growth  12% 10% 10% 10% 
EBITDA 336 398 439 484 534 
Net Income 235 281 315 354 406 
Net Debt -316     
PER 24     
PBV 9     
            
Source: Itaú BBA report and own calculations 
The analyst NOR estimations are in line with the ones projected for the equity valuation of 
OdontoPrev, being particularly higher in 2019, R$ 1,967 vs. R$ 1,874. The net income 
forecast presents higher figures also in 2019, R$ 442 vs. R$ 406. The dissimilarity of the 
analyst valuation from the one performed will lie in the cost of equity, which will be greater, 
thus offsetting this differences and equaling both valuations. 




The cost of capital assumed by the analyst in this valuation varies over the explicit period, 
where inflation differential oscillates, resulting in a Re of 13.6%, on average (see Appendix 
13). The growth rate used for the terminal value perpetuity is 5% - in line with the growth 
rate estimated for this valuation.  
By discounting the future dividends and calculating the terminal value, the analyst reached 
to a total equity value of the company of R$ 5,236 million, correspondent to the equity value 
per share of R$ 9.9. After that the dividend of 2015 is added – R$ 0.4, giving a total equity 
value per share of R$ 10.3. 
Table 9 – Valuation performed by Itaú BBA’s analyst 
Itaú BBA Valuation (R$ million) 2015 
Equity Value 3231 
Perpetuity Value (g=5%) 2005 
Total equity value 5236 
Equity per share 9.9 
Dividend per share 2015 0.4 
Analyst Fair value  10.30 
OdontoPrev 10.45 
    
Source: Itaú BBA report and own calculations. 
The value per share estimated by the analyst is very close to the one calculated in the DCF 
valuation of this thesis, so the only fact one could retain is that when close assumptions are 
used (i.e. NOR and Re), undertaken by a different equity valuation method, the results 
provide similar outcomes. It is important to stress that the estimated share price of the 
company is very close to the consensus of all the investment banks covering the company - 








5.  Conclusion and Limitations 
The objective of this master thesis is to value the price of OdontoPrev’s stock, through the 
application of diverse valuation methods, each of them leading to different outcomes. The 
first conclusion is that the valuation model chosen has to be adapted to match the company 
structure and industry sector, leading to accurate assumptions about future performance. 
The DCF Valuation – FCFE is considered the most relevant method for valuing OdontoPrev, 
being relative valuation used as a benchmark to confirm the DCF price per share of R$ 10.45, 
an upside of 6.7% comparatively to the price on the 28th of August 2015.  
One limitation of this thesis is the fact that the company only started to disclosure the 
revenues breakdown by segment in the first semester of 2015, with lack of detailed past 
information. If the historical performance by segment had been provided, the precision of the 
revenues’ forecast would be higher, because each of the operational segments follows a 
different selling strategy and also distinct growth opportunities and margins. 
The proposed estimated fair value of OdontoPrev was achieved with the academic support 
of all the models stated above, data from the IMF and with the personal judgement over the 
company’s future performance. Since the company operates in a very volatile market, none 








Appendix 1 – Additional Literature Review 
1.4.8.1 Residual Income Valuation 
According to (Stowe et al., 2007), residual income valuation analyzes the intrinsic value of 
equity in two main sections: the current equity book value and the present value of expected 
future residual income17. The value of the stock can be expressed as follows: 
Equation 15 – Residual Income Valuation 
 
𝑉0 = 𝐵0 + ∑ (1







  𝑉𝑜 =  𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑎 𝑠ℎ𝑎𝑟𝑒  
  𝐵𝑜 = 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 𝑏𝑜𝑜𝑘 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 
  𝐵𝑡 =  𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 𝑏𝑜𝑜𝑘 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 𝑎𝑡 𝑎𝑛𝑦 𝑡𝑖𝑚𝑒 𝑡  
   𝑟 = 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑡𝑢𝑟𝑛 𝑜𝑛 𝑒𝑞𝑢𝑖𝑡𝑦 (𝑐𝑜𝑠𝑡 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦) 
   𝐸𝑡 =  𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐸𝑃𝑆 𝑓𝑜𝑟 𝑝𝑒𝑟𝑖𝑜𝑑 𝑡  
   𝐵𝑜 = 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 𝑏𝑜𝑜𝑘 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 
   𝑅𝐼 = 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑖𝑛𝑐𝑜𝑚𝑒 , 𝑒𝑞𝑢𝑎𝑙 𝑡𝑜 𝐸𝑡 − 𝑟𝐵𝑡 − 1  
The residual income approach starts the valuation process in a different way comparatively 
to other DCF models: the valuation begins with the book value of equity and then adjusts this 
value by adding the present values of the expected future residual income.  
After the estimations of future residual incomes during the explicit period, a continuing 
residual income (after the forecasted horizon) is projected for the future. According to (Stowe 
et al., 2007), “unlike in other models, the terminal value is not a major driver of value in a 
residual income approach”. This fact differentiates this model from the other DCF models, 
where the influence of the terminal value in the valuation is substantially higher. 
                                                             
17 The amount of income that a company has left after all debt paid. 




1.4.9 Contingent Claim Valuation 
Contingent Claim valuation uses option pricing models to measure the value of the company, 
for instance Black Scholes model. The method is indicated for industries where the 
investment is intensive and there is a high degree of uncertainty (Frykman & Tolleryd, 2003) 
A contingent claim only pays off under certain circumstances, so this option-pricing model 
tries to measure a value of an asset based on expectations and probabilities about a future 
event. According to (Damodaran, 2005), this valuation method brings a revolutionary 
discussion where “the value of an asset may be greater than the present value of expected 
cash flows if the cash flows are contingent on the occurrence or not nonoccurrence of an 
event”. 
According to (Damodaran, 2005), a good example of where this valuation makes sense is oil 
reserves, i.e. Petrobras, the biggest Brazilian oil company: The valuation of an oil reserve 
could be valued based on future oil prices; however, these predictions will miss the fact that 
Petrobras will only develop the oil reserve if oil prices go up, thus option pricing models 
takes into consideration this view. 
1.4.10 Liquidation and Accounting Valuation 
Liquidation and accounting valuation tend to arrive at the company’s residual value assuming 
that the company sells of all assets and pays off all the liabilities. Liquidity value may be 
different from the book value because when a company sells of all the assets may receive 
less than its market value. Valuing the existing assets of a firm with accounting estimates or 
book value often used as a starting point (Damodaran, 2005). This valuation approach 
proposes that a value of a company is the sum of the values of the individual assets owned 
by the business. 
Concluding, these two methods are useful in exceptional circumstances, however the 
situation of the company, industry and financial condition are not exceptional, so these two 








Appendix 2 – Beta Calculation 
 





Appendix 3 – OdontoPrev Membership Growth vs. Dental Plans and Healthcare 
Plans (Medical Plans) - (values in million). 
 
Source: ANS and own calculations.  
ODPV3
4y Beta 0.31 Beta 0.41 Beta 0.29
5y Beta 0.36 Beta 0.44 Beta 0.31
Daily Weekly Monthly
∆% Dental Plans ∆% Healthcare Plans ∆%
2000 447         17.2% 0% 2,603              0.0% 31,161            0.0%
2001 544         17.8% 22% 3,063              17.7% 31,727            1.8%
2002 613         16.7% 13% 3,678              20.1% 31,513            -0.7%
2003 763         17.6% 24% 4,326              17.6% 32,075            1.8%
2004 943         17.7% 24% 5,313              22.8% 33,841            5.5%
2005 1,132      18.2% 20% 6,204              16.8% 35,441            4.7%
2006 1,492      20.3% 32% 7,350              18.5% 37,248            5.1%
2007 2,113      23.1% 42% 9,164              24.7% 39,316            5.6%
2008 2,460      22.2% 16% 11,061            20.7% 41,468            5.5%
2009 4,175      31.5% 70% 13,260            19.9% 42,575            2.7%
2010 4,978      34.3% 19% 14,511            9.4% 44,923            5.5%
2011 5,533      32.8% 11% 16,854            16.1% 46,145            2.7%
2012 5,976      31.6% 8% 18,914            12.2% 47,866            3.7%
2013 6,172      30.6% 3% 20,144            6.5% 49,495            3.4%
2014 6,316      29.7% 2% 21,263            5.6% 50,820            2.7%
Market Share
ANS - Total Members (thousand)
OdontoPrevYear

























Source: OdontoPrev Corporate Presentation September 2015.




















Appendix 7 – Net Operational Revenue Breakdown and Projections 
 
Source: OdontoPrev Annual Reports and own calculations. 
REVENUES (R$ thousand) 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E 2021E
Members 5,976          6,172          6,316          
 Average Members 5,755          6,074          6,244          6,488          6,754          7,121          7,508          7,917          8,347          8,801          
Growth 9% 6% 3% 4% 5% 5% 5% 5% 5% 5%
Average Ticket (R$/Live/Month) (NOR) 13.84          14.67          15.43          16.64          17.44          18.20          18.95          19.73          20.52          21.35          
Growth 4% 6% 5% 8% 5% 4% 4% 4% 4% 4%
Efective Inflation  & Expected Inflation 6% 6% 6% 8% 5% 5% 5% 5% 4% 4%
Growth / Inflation (%) 77% 103% 80% 98% 90% 90% 90% 90% 90% 90%
NOR 955,483      1,069,606   1,156,121   1,295,615   1,413,574   1,554,831   1,707,429   1,874,047   2,055,752   2,255,074   
Growth 14% 12% 8% 12% 12% 10% 10% 10% 10% 10%




Appendix 8 – Cost of Services Breakdown and Projections 
 
 
Source: OdontoPrev Annual Reports and own calculations. 
 
Appendix 9 – Brasildental (Joint Venture) – Income Statement Forecast 
 
Source: Own calculations. 
BRASILDENTAL (thousands) 2015 2016E 2017E 2018E 2019E 2020E 2021E
Revenues
Banco do Brasil Employees 280                277                283                286                286                287                287                
Growth (GDP, cosntant) -1% 1% 2% 2% 2% 2% 2%
Average Ticket (R$/Live/Month) 11.00             11.86             12.43             12.97             13.51             14.06             14.63             
Growth / Inflation (%) 8% 5% 4% 4% 4% 4% 4%
NOR Employees 36,960           39,451           42,192           44,566           46,441           48,403           50,388           
Banco do Brasil - Distribution channel 300                600                900                1,350             1,688             1,941             2,135             
Growth 100% 50% 50% 25% 15% 10% 5%
% Banco do Brasil Members 1% 1% 2% 2% 3% 3% 4%
Average Ticket (R$/Live/Month) 23.44             25.28             26.50             27.64             28.79             29.97             31.18             
Growth / Inflation (%) 8% 5% 4% 4% 4% 4% 4%
NOR Distribution Channel 84,376           181,993         286,147         447,759         582,925         697,827         798,602         
NOR (Total) 121,336         221,444         328,339         492,325         629,367         746,230         848,990         
-Cost of Services 37,639           101,864         151,036         226,469         289,509         343,266         390,535         
% NOR 31% 46% 46% 46% 46% 46% 46%
-Selling expenses 8,436             15,571           22,855           33,870           42,771           50,067           56,236           
% NOR 7% 7% 7% 7% 7% 7% 7%
-Administrative Expenses 12,251           25,479           40,061           62,686           81,610           97,696           111,804         
% NOR 15% 14% 14% 14% 14% 14% 14%
EBITDA 63,011           78,530           114,387         169,299         215,477         255,201         290,414         
-Depretiation 12.13             22.14             32.83             49.23             62.94             74.62             84.90             
% NOR 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
EBIT 62,999           78,508           114,354         169,250         215,414         255,127         290,329         
+Financial Results 12.13             22.14             32.83             49.23             62.94             74.62             84.90             
% NOR 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
EBT 63,011           78,530           114,387         169,299         215,477         255,201         290,414         
Taxes 18,273           22,774           33,172           49,097           62,488           74,008           84,220           
% EBT 29% 29% 29% 29% 29% 29% 29%
Net Income 44,738           55,756           81,215           120,202         152,989         181,193         206,194         
DPR 50% 50% 50% 50% 75% 75% 75%
Dividend 22,369           27,878           40,607           60,101           114,742         135,895         154,646         
OdontoPrev's stake (25%) 5,592             6,970             10,152           15,025           28,685           33,974           38,661           
COST OF SERVICES (R$ thousand) 2011 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E 2021E
Cost of services 416,464 -     485,528 -     501,165 -     548,837 -     591,203 -     650,244 -     715,222 -     785,417 -     862,062 -     945,646 -     1,037,334 -  
 % NOR 50% 51% 47% 47% 47% 46% 46% 46% 46% 46% 46%
Claims 352,470 -     426,859 -     451,644 -     476,031 -     514,876 -     567,654 -     628,191 -     689,844 -     757,163 -     830,576 -     911,107 -     
% NOR 42% 45% 42% 41% 41% 40% 40% 40% 40% 40% 40%
% Cost of Services 85% 88% 90% 87% 87% 87% 88% 88% 88% 88% 88%
Payroll charges on services 26,564 -       29,882 -       31,839 -       32,926 -       
% Cost of Services 6% 6% 6% 6%
Dental materials 4,025 -         3,781 -         4,582 -         4,643 -         
% Cost of Services 1% 1% 1% 1%
Other expenses 33,405 -       25,006 -       13,100 -       35,237 -       29,560 -       32,512 -       35,761 -       39,271 -       43,103 -       47,282 -       51,867 -       
   Others 21,764 -       19,950 -       
   Provision of events that occured (PEONA) 8,664          15,287 -       3,312 -         9,299 -         9,299 -         9,299 -         9,299 -         9,299 -         8,301 -         
% Cost of Services 8% 5% 3% 6% 5% 5% 5% 5% 5% 5% 5%
NOR 835,263     955,483     1,069,606  1,156,121  1,257,878  1,413,574  1,554,831  1,707,429  1,874,047  2,055,752  2,255,074  




Appendix 10 – CAPEX and Depreciations Forecast 
 







Appendix 11– Net Working Capital Forecast 
 
Source: Own calculations.
CAPEX & Depretiation (R$ thousand) 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
CAPEX 7,000          10,600        10,900        18,500        16,000        17,600        19,360        21,296        23,426        25,768        28,345        
%NOR 0.8% 1.1% 1.0% 1.6% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%
NOR 835,263      955,483      1,069,606   1,156,121   1,257,878   1,413,574   1,554,831   1,707,429   1,874,047   2,055,752   2,255,074   
Depreciation 6,173          5,159          5,140          6,761          7,500          7,875          8,269          8,682          9,116          9,572          10,051        
% Gross PPE 36.2% 35.0% 34.1% 28.4% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0%
Gross PPE 17,067        14,748        15,064        23,787        25,000        26,250        27,563        28,941        30,388        31,907        33,502        
NWC MAP (R$ thousand) 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Healthcare Receivables 88,572         100,305       85,627         99,117         118,494       133,161       146,467       160,842       176,538       193,655       212,431       
DSO (days) 39 38 29 31 34 34 34 34 34 34 34
Advances 10,137         9,499            11,321         8,971            12,711         14,285         15,712         17,254         18,938         20,774         22,788         
DSO (days) 4 4 4 3 4 4 4 4 4 4 4
Var (Receivables) 11,095         12,856 -        11,140         23,117         16,240         14,734         15,917         17,379         18,953         20,791         
NOR 835,263       955,483       1,069,606   1,156,121   1,257,878   1,413,574   1,554,831   1,707,429   1,874,047   2,055,752   2,255,074   
Suppliers 9,694            8,916            14,728         10,192         13,243         14,565         16,021         17,593         19,310         21,182         23,236         
DPO (days) 8 7 11 7 8 8 8 8 8 8 8
Other Liabilities 30,949         23,185         33,703         33,556         37,017         40,714         44,783         49,178         53,977         59,211         64,951         
DPO (days) 27 17 25 22 23 23 23 23 23 23 23
Var (Payables) 8,542 -           16,330         4,683 -           6,512            5,019            5,524            5,968            6,516            7,106            7,795            
Cost of Services 416,464       485,528       501,165       548,837       591,203       650,244       715,222       785,417       862,062       945,646       1,037,334   
Stock 784               987               954               932               1,134            1,247            1,372            1,506            1,653            1,814            1,989            
DSI (days) 1 1 1 1 1 1 1 1 1 1 1
Var (Stock) 203               33 -                22 -                202               113               125               135               147               160               176               
Cost of Services 416,464       485,528       501,165       548,837       591,203       650,244       715,222       785,417       862,062       945,646       1,037,334   
NWC (AR-AP+S) 78,690         49,471         65,272         82,079         93,413         102,748       112,832       123,843       135,850       149,022       
Var (NWC) 29,219 -        15,801         16,807         11,334         9,335            10,084         11,011         12,008         13,172         




Appendix 12 - Income Statement for the Explicit Period – Net Income Forecast  
 




Appendix 13 – Analyst Assumptions – Cost of Equity Calculation 
 
Source: Report Itaú BBA, 20th July 2015. 
 
INCOME STATEMENT (R$ thousand) 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E 2021E
Net Operating Revenue (NOR) 955,483     1,069,606  1,156,121  1,257,878  1,413,574  1,554,831  1,707,429  1,874,047  2,055,752  2,255,074  
NOR Growth 14.4% 11.9% 8.1% 8.8% 12.4% 10.0% 9.8% 9.8% 9.7% 9.7%
Cost of services 485,528 -    501,165 -    548,837 -    591,203 -    650,244 -    715,222 -    785,417 -    862,062 -    945,646 -    1,037,334 - 
% NOR 50.8% 46.9% 47.5% 47.0% 46.0% 46.0% 46.0% 46.0% 46.0% 46.0%
Gross Income 469,955     568,441     607,284     666,676     763,330     839,609     922,012     1,011,986  1,110,106  1,217,740  
% NOR 49.2% 53.1% 52.5% 53.0% 54.0% 54.0% 54.0% 54.0% 54.0% 54.0%
   Selling expenses 88,832 -      99,226 -      109,446 -    116,604 -    132,530 -    144,307 -    156,620 -    169,811 -    183,903 -    199,165 -    
   % NOR 9.3% 9.3% 9.5% 9.3% 9.4% 9.3% 9.2% 9.1% 8.9% 8.8%
Contribution Margin 381,123     469,215     497,838     550,072     630,800     695,302     765,391     842,174     926,203     1,018,575  
%NOR 39.9% 43.9% 43.1% 43.7% 44.6% 44.7% 44.8% 44.9% 45.1% 45.2%
   Administrative expenses 147,643 -    159,747 -    171,421 -    182,632 -    197,900 -    217,676 -    239,040 -    262,367 -    287,805 -    315,710 -    
   % NOR 15.5% 14.9% 14.8% 14.5% 14.0% 14.0% 14.0% 14.0% 14.0% 14.0%
   Other Operating Expenses 32,824 -      46,485 -      51,492 -      47,735 -      50,813 -      55,149 -      59,829 -      64,935 -      70,500 -      76,599 -      
   % NOR 3.4% 4.3% 4.5% 3.8% 3.6% 3.5% 3.5% 3.5% 3.4% 3.4%
      Allowance for doubtful receivables 22,566 -      35,840 -      33,316 -      31,447 -      35,339 -      38,871 -      42,686 -      46,851 -      51,394 -      56,377 -      
      %NOR 2.4% 3.4% 2.9% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5%
      Stock option 3,624 -        6,350 -        7,738 -        8,419 -        7,556 -        8,311 -        9,126 -        10,017 -      10,988 -      12,054 -      
      %NOR 0.4% 0.6% 0.7% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5%
      Profit sharing 6,634 -        4,295 -        10,438 -      7,868 -        7,918 -        7,967 -        8,017 -        8,067 -        8,118 -        8,168 -        
      %NOR 0.7% 0.4% 0.9% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6%
   Equity in subsidiaries 728 -           102            1,470 -        5,592         6,970         10,152       15,025       28,685       33,974       38,661       
   % NOR -0.1% 0.0% -0.1% 0.4% 0.5% 0.7% 0.9% 1.5% 1.7% 1.7%
Income before finance income and taxes (EBIT) 199,928     263,085     273,455     325,297     389,056     432,629     481,547     543,558     601,871     664,927     
% NOR 20.9% 24.6% 23.7% 25.9% 27.5% 27.8% 28.2% 29.0% 29.3% 29.5%
   Net Financial Income 13,233       11,914       14,696       16,543       13,746       14,304       14,325       14,726       14,577       14,336       
   % NOR 1.4% 1.1% 1.3% 1.3% 1.0% 2.0% 1.8% 1.7% 1.5% 1.4%
      Financial income 22,674.00  23,533.00  33,842.00  27,313.20  26,703.64  26,813.17  27,641.00  28,462.60  27,386.72  27,401.43  
      %NOR 2.4% 2.2% 2.9% 2.2% 1.9% 1.7% 1.6% 1.5% 1.3% 1.2%
      Financial expenses 42,085.00 - 44,828.00 - 51,987.00 - 45,140.80 - 46,570.76 - 46,122.31 - 46,929.77 - 47,350.13 - 46,422.76 - 46,679.15 - 
      %NOR 4.4% 4.2% 4.5% 3.6% 3.3% 3.0% 2.7% 2.5% 2.3% 2.1%
      Interest on capital (IOC) 32,644.00  33,209.00  32,841.00  34,370.20  33,613.25  33,613.25  33,613.25  33,613.25  33,613.25  33,613.25  
      %NOR 3.4% 3.1% 2.8% 2.7% 2.4% 2.2% 2.0% 1.8% 1.6% 1.5%
      %Capital 6.4% 6.6% 6.5% 6.9% 6.6% 6.6% 6.6% 6.6% 6.6% 6.6%
Income before taxes and profit sharing (EBT) 213,161     274,999     288,151     341,840     402,802     446,933     495,872     558,283     616,449     679,263     
   Current tax 47,062 -      77,814 -      83,339 -      98,867 -      116,498 -    129,262 -    142,303 -    153,170 -    168,463 -    185,275 -    
   % EBT 22.1% 28.3% 28.9% 28.9% 28.9% 28.9% 28.7% 27.4% 27.3% 27.3%
   Deferred tax 20,336 -      8,749 -        9,820 -        8,198 -        6,177 -        3,233 -        -             -             -             -              
   % EBT 9.5% 3.2% 3.4% 2.4% 1.5% 0.7% 0.0% 0.0% 0.0% 0.0%
Net income before participation of minoritary shareholders 145,763.0  188,436.0  194,992.0  234,774.8  280,126.9  314,437.9  353,568.4  405,113.2  447,985.4  493,988.4  
   Participation of minoritary shareholders 197.0 -        345.0 -        283.0 -        335.7         402.8         446.9         495.9         558.3         616.4         679.3         
     % EBT 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
Net income (IFRS) 145,566     188,091     194,709     235,111     280,530     314,885     354,064     405,671     448,602     494,668     
% NOR 15% 18% 17% 19% 20% 20% 21% 22% 22% 22%
DDM 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Discounted Div (R$ million) 262 259 284 282 286 281 271 257 236 222 209 197 185
Ke 14.4% 14.2% 13.9% 13.7% 13.4% 13.4% 13.4% 13.4% 13.4% 13.4% 13.4% 13.4% 13.4%
Beta 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90
Rf 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9% 2.9%
ERP 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4%
Average Inflation Differential 3.4% 3.2% 2.9% 2.7% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4%
Country Risk Premium 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3% 2.3%























Investment Bank Price (R$) Date
Banco do Brasil 12.6 July 2015
Brasil Plural 8.5 July 2015
BTG Pactual 10.5 March 2015
Credit Suisse 11.0 July 2015
HSBC 11.0 August 2015
Itaú BBA 10.3 July 2015
JPMorgan 11.0 July 2015
J.Safra 10.0 July 2015
UBS 12.3 July 2015
Votorantim Corretora 10.9 July 2015
Average 10.8 July 2015
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